Proteomics of Severe Traumatic Brain Injury: A Feasibility Study
NCT ID: NCT00522496
Last Updated: 2009-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
8 participants
OBSERVATIONAL
2007-07-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imaging of Traumatic Brain Injury
NCT01196299
TBI-Prognosis Multicenter Prospective Study
NCT02452541
Multiomic Analysis of Serum in Acute Period of Traumatic Brain Injury
NCT05867992
Rapid MRI for Assessing Functional Abilities and Predicting TBI Outcomes
NCT06454591
Application of Circulating Extracellular Vesicles in Early Disease Assessment and Prognosis After Traumatic Brain Injury
NCT05279599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has GCS less than 9
* Patient requires intracranial pressure monitoring
* Patient life expectancy greater than 72 hours
Exclusion Criteria
* Patient is less than 18 years of age
* Patient does not require intracranial pressure monitoring
* Patient has life expectancy less than 72 hours
* Patient has GCS greater or equal to 9
* Patient is currently enrolled in another study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Intensive Care Foundation
OTHER
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Calgary
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zygun A David, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foothills Medical Centre
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20216
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.